TRIALSITEIQ PUBLIC FEASIBILITY SCORECARD · GRADE C

NCT06933069: A Multicenter, Open-label Phase I Clinical Study to Evaluate the Safety, Tolerability, Pharmacokinetic Profile and Preliminary Anti-tumor Activity of CMAB017 in Advanced Malignant Solid Tumors

Sponsor: Taizhou Mabtech Pharmaceutical Co.,Ltd · Phase: PHASE1 · Area: ONCOLOGY · Target Enrollment: 55 pts

Competing Trials Overlap

2 Active Trials

Excess Burn Exposure

$10,053,120

Rescue Site Savings

+$6,628,776

Unlock Full NCT06933069 Backup Super-Site Packet ($49 One-Time Pass)

Download the complete list of top-decile low-cannibalization clinical sites, verified Principal Investigator (PI) direct emails/phones, and protocol optimization benchmarks.

Download $49 NCT06933069 Rescue Dossier →